Dr Reddy’s relaunches over-the-counter Famotidine Tablets in the US market

In October 2017, Dr Reddy’s had recalled 569,000 store-brand famotidine tablets in the U.S. due to failed tests for impurities and degradation and it was its second recall of the same medication since July 2016.

Dr Reddy’s has relaunched over-the-counter (OTC) Famotidine Tablets in the US market. It prevents and relieves heartburn as well as decreases stomach acid production brought on by eating or drinking certain food and beverages. The drug starts working within an hour.

Over-the-counter drugs are those medicines which are directly sold to the consumers without a prescription from a healthcare professional.

In October 2017, Dr Reddy’s had recalled 569,000 store-brand famotidine tablets in the U.S. due to failed tests for impurities and degradation and it was its second recall of the same medication since July 2016.

The medicines were sold at CVS pharmacies classifying as Class III recall. According to the United States, Food and Drug Administration recall policies, Class III recall means that the suspect drugs aren’t likely to cause injury to humans.

In July 2016, Dr Reddy’s pulled more than 84,000 famotidine tablets and also produced for CVS. In both cases, the company was found an out-of-specification result during routine stability testing.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time